



Review

Mitochondrial Complex I, a Possible Sensible Site of cAMP Pathway in Aging

Anna Signorile¹ and Domenico De Rasmò^{2,*}¹ Department of Translational Biomedicine and Neuroscience, University of Bari Aldo Moro, 70124 Bari, Italy² Institute of Biomembranes, Bioenergetics and Molecular Biotechnology (IBIOM), National Research Council (CNR), 70126 Bari, Italy

* Correspondence: d.derasmò@ibiom.cnr.it; Tel.: +39-080-544-8516

Abstract: In mammals during aging, reactive oxygen species (ROS), produced by the mitochondrial respiratory chain, cause oxidative damage of macromolecules leading to respiratory chain dysfunction, which in turn increases ROS mitochondrial production. Many efforts have been made to understand the role of oxidative stress in aging and age-related diseases. The complex I of the mitochondrial respiratory chain is the major source of ROS production and its dysfunctions have been associated with several forms of neurodegeneration, other common human diseases and aging. Complex I-ROS production and complex I content have been proposed as the major determinants for longevity. The cAMP signal has a role in the regulation of complex I activity and the decrease of ROS production. In the last years, an increasing number of studies have attempted to activate cAMP signaling to treat age-related diseases associated with mitochondrial dysfunctions and ROS production. This idea comes from a long-line of studies showing a main role of cAMP signal in the memory consolidation mechanism and in the regulation of mitochondrial functions. Here, we discuss several evidences on the possible connection between complex I and cAMP pathway in the aging process.

Keywords: cAMP; complex I; signaling; mitochondria; aging



Citation: Signorile, A.; De Rasmò, D. Mitochondrial Complex I, a Possible Sensible Site of cAMP Pathway in Aging. *Antioxidants* **2023**, *12*, 221. <https://doi.org/10.3390/antiox12020221>

Academic Editor: Jiankang Liu

Received: 30 December 2022

Revised: 16 January 2023

Accepted: 17 January 2023

Published: 18 January 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

During aging, reactive oxygen species (ROS), produced by the mitochondrial respiratory chain, cause the oxidative damage of macromolecules leading to respiratory chain dysfunction, which in turn increases ROS production. Several forms of neurodegeneration, and other common human diseases, are often associated with mitochondrial dysfunctions, oxidative stress and aging [1,2]. Therefore, attempts to modulate ROS levels have been carried out in order to understand the role of oxidative stress in aging and aging related diseases. Mitochondrial free radical production is considered to be one of the main causes involved in the determination of longevity [2]. The complex I of the mitochondrial respiratory chain is the major source of ROS production [3,4] and the mitochondrial ROS production, specifically at complex I, has been proposed as one of the major determinants for longevity and is involved in several age-associated neurological diseases [2,5].

The cAMP/PKA pathway has a role in the regulation of the respiratory chain activity [6–9] and in particular complex I [10–12], ROS production [10,13] and mitochondrial biogenesis [14,15]. In addition, it has been found that several anti-aging molecules such as the hydroxytyrosol of olive oil [16] and the resveratrol of red wine [17], modulate cAMP pathway, respiratory chain activity and mitochondrial biogenesis [17–19]. The cAMP/PKA system appears also to have a role in several neurodegenerative diseases associated with mitochondrial dysfunction, oxidative stress and aging, such as Parkinson's disease (PD) [20,21], Alzheimer's disease [22,23] and Down syndrome [24]. It is noteworthy that the activation of the cAMP pathway restores the mitochondrial activity and lowers the

ROS level in the mentioned diseases [20,21,24–26]. In addition, all members of the cAMP pathway are present in the mitochondria [27–30], where they can regulate mitochondrial complex I [31], complex IV [32] and ATP synthase [33] activities, ATP production [34], ROS production [32] and susceptibility towards apoptosis [35].

Both complex I and cAMP system are strictly connected to aging processes. Herein, evidence on the possible connection between complex I and cAMP pathway in aging are reported.

2. Mitochondrial Complex I

The mammalian complex I is the largest mitochondrial respiratory chain enzyme and it is composed of 45 constituent subunits. Seven subunits are encoded by the mitochondrial DNA, 38 by nuclear genes [36]. 14 subunits are conserved from procaryotes to eucaryotes and constitute the catalytic core that maintains the minimal structure for its catalytic activity. The others 31 subunits are called supernumerary. The function of the supernumerary subunits is largely unknown. Some are involved in the assembly and regulation of the complex [8,36–39]. Complex I is involved in apoptosis [40] and age-related functional decline [41] as well as in a number of metabolic [38], degenerative [42] and proliferative diseases [43]. It is the entry point of NADH reducing equivalents in the mitochondrial respiratory chain catalyzing the electron transport from NADH to ubiquinone. This process is coupled to proton pump from the matrix to intermembrane space, thus conserving the free energy as a transmembrane potential [44]. The transmembrane potential drives ATP formation by complex V. In complex I, several redox centers have been found (FMN, iron-sulfur clusters, and tightly bound ubiquinone), which transfer electrons from the enzyme-bound NADH to the ubiquinone [44] (Figure 1). The complex I structure has a well-known “L” shape with a membrane hydrophobic arm and a matrix-exposed hydrophilic arm. It can be subdivided into three functional modules named N-module (NADH binding and oxidation), Q-module (electron transfer to ubiquinone) and P-module (proton pumping) [45] (Figure 1). Beyond the entry point of reducing equivalents, complex I is also considered to be the major source of reactive oxygen species (ROS) production [3,4] indeed it can also transfer single electrons to oxygen with formation of oxygen superoxide [41,46]. Complex I has been found to produce ROS at FMN and probably iron sulphur cluster N2 [47–51] in the hydrophilic arm (Figure 1).

Several conditions can generate an increase of complex I-dependent ROS production, for example, an excessive reducing power can result in the overproduction of ROS in the mitochondrial matrix with oxidative damage of mitochondrial DNA and subunits of complex I exposed to this space. Complex I can produce anion superoxide during forward electron transfer [4] but it becomes the most important site of superoxide production within mitochondria during reverse electron transfer (RET) [52]. RET is the process, driven by the inner mitochondrial membrane potential, by which electrons from the reduced ubiquinone pool (supplied by succinate dehydrogenase, glycerol-3-phosphate dehydrogenase, electron-transferring flavoprotein or dihydroorotate dehydrogenase) pass through complex I reducing NAD^+ to NADH [52].

Complex I is a pacemaker of the oxidative phosphorylation system for ATP production [53,54] and its functional capacity is regulated, at transcription and post-translational levels, in response to a variety of regulatory factors/events [8,9,14,38]. In mammals, complex I biogenesis depends on the coordinated expression of mitochondrial and nuclear genes and involves nucleus/cytosol/mitochondria protein traffic and the stepwise assembly of a 45 subunits oligomer [37]. In addition to “de novo” assembly of complex I from all the subunits, an exchange of individual subunits, between the newly imported ones and the older already assembled in the complex, can also occur [37,55]. This process can play a proof-checking role of the subunits in the complex, in particular those superficially exposed to the matrix space, where they can be oxidatively-damaged by ROS, with depression of the catalytic activity. The content of complex I is determined, as for all proteins, by the balance between protein expression and proteolysis. This turnover is particularly critical

for complex I because the subunits of its hydrophilic arm are directly subjected to oxidation in the mitochondrial matrix by ROS produced by the complex itself. The functional capacity of complex I appears also to be linked to mitochondrial dynamics [1]. Moreover, the complex I can assemble at higher order with complex II, complex III and complex IV to form supercomplexes [56] in order to modulate the capacity and efficiency [57–59] of respiratory chain and the ROS production [59].




Figure 1. Schematic representation of mammalian complex I. (A) Complex I with “L” shape is shown in three distinct modules: N-module (in green), Q-module (in pink) and P-module (in blue). N and Q modules constitute the hydrophilic arm of complex I, exposed in the matrix [45]. The P-module constitutes the hydrophobic arm of the complex embedded in the mitochondrial inner membrane (MIM) [45]. The oxidation of NADH by FMN generates the electrons transfer, through the seven iron–sulfur clusters (yellow spheres), to ubiquinone molecule [44]. The reduction of ubiquinone induces conformational changes in the P-module. This results in proton pumping from matrix to intermembrane space. The reduced FMN, and probably the N2 iron–sulfur cluster, can also react with molecular oxygen (O_2) to form superoxide anion (O_2^-). (B) The complex I subunits belonging to N, Q and P modules are reported [47–51].

3. Mitochondrial Complex I in Aging

In mammals, a functional decline of mitochondrial respiratory chain activity and thus of complex I has been reported during the aging process, associated with an increased ROS production [41]. For example a study of human skeletal muscle of 63 orthopedic patients of age ranging between 17 and 91 years showed a statistically significant decrease with aging of mitochondrial oxygen consumption with pyruvate plus malate, succinate and ascorbate plus TMPD associated with an age-dependent decrease of the enzymatic activity of complex I, II and IV [60]. It has been suggested that the aging-dependent decline of complex I activity is caused by a decreased expression and increased oxidation of complex I subunits [61,62]. In agreement, several neurodegenerative diseases, such as Parkinson’s disease, are also associated with a decrease of complex I activity and content and an increase of mitochondrial ROS production and complex I subunit oxidation [1,26,42,63,64]. The free radical theory of aging postulates that mitochondrial ROS production causes oxidative damage of macromolecules leading to mitochondrial respiratory chain dysfunction which, in turn, increases ROS production [5]. The complex I, together with complex III, of the mitochondrial respiratory chain is considered the major source of ROS production [41]. Some redox centers, such as FMN radical and ubiquinone in complex I, can be directly oxidized by dioxygen with the single electron transfer to O_2 and the production of oxygen superoxide [4,46]. Oxygen superoxide can directly oxidize proteins, lipids and nucleic acids. However, complex I produces ROS mainly during reverse electron transport in which electrons pass through complex I reducing NAD^+ to NADH [52]. This can happen

in the condition of reduced ubiquinone, accumulated succinate and higher proton motive force [52].

Mitochondrial ROS production, specifically at complex I, is considered to be one of the main causes involved in the aging process and has been proposed as one of the determinants for longevity of species [41,65–67]. Indeed, a comparative approach of complex I in the heart tissue of eight different mammalian species with a longevity ranging from 3.5 to 46 years showed a specific difference in the gene and protein expression of complex I related to longevity, and in particular that longevity phenotype is associated with low protein abundance of matrix hydrophilic subunits NDUFV2 and NDUF4 of complex I [68]. These differences were also associated with reduced ROS levels [68]. Accordingly, a low rate of mitochondrial ROS production has been observed in long-lived organisms, invertebrates and vertebrates, with respect to short lived [66,67]. At the molecular level, the oxidation of mitochondrial DNA and membrane lipids appears to be the traits that correlate with longevity across species. In fact, a negative correlation between mitochondrial DNA oxidation, lipid peroxidation and longevity has been observed, that means a lower oxidation in long- than in short-lived animals even in the same species [69,70].

In the last years, interesting evidences have been provided on the role of content of complex I and ROS production, on the lifespan. The content of complex I, and, in particular, that part of complex I responsible for ROS production, appears to positively correlate with ROS production [71]. Importantly, in mouse and rat, nutritional or pharmacological treatments such as protein or methionine restriction, rapamycin or metformin (inhibitor of complex I) treatment, resulted in higher longevity associated with a decrease of complex I-dependent ROS production [69,72–75] in heart, skeletal muscle, liver and brain [76]. Moreover, dietary restriction has been also associated with a decrease in the content of complex I [65].

As mentioned above, the longevity-related ROS production by complex I has been ascribed to the peripheral arm [71], and thus to FMN and/or FeS centers [47–51]. In line with this, a study showed that mice under dietary restriction activate an adaptive response leading to a decrease of respiratory chain subunits and, in particular, those that belong to the hydrophilic peripheral arm of complex I [71]. This change has been associated again with a decreased superoxide production at complex I and the improvement of the complex assembly [71]. On the contrary, the inhibition of complex I assembly increased mitochondrial ROS production accelerating aging [71]. The data of the abundance of complex I hydrophilic peripheral subunits have been associated with ROS level [71]. In particular, it has been shown that young longer living mice had a low level of subunits of the hydrophilic arm of complex I compared to old or shorter-living mice, while the hydrophobic arm subunits levels remained unaltered [71]. The authors propose that if the amount of hydrophilic arm subunits is higher than the amount of the hydrophobic arm subunits, the hydrophilic subunits can also assemble into a subcomplex that is able to oxidize respiratory substrate without coupling the proton pumping. This process leads to ROS production that, in turn, accelerates the aging process [71]. This is in agreement with the metabolic labeling study in mammals showing that hydrophilic arm subunits of mitochondrial complex I have a shorter half-lives than hydrophobic arm subunits in liver and heart [77] and in HEK cell line [78]. This supports the hypothesis that the hydrophilic arm subunits of complex I might exist as free [31] or less stable monomer [71] in according also to the finding showing that the new-imported subunits of the hydrophilic peripheral arm of complex I can be assembled in the complex I in exchange with the “older oxidated” ones already assembled in the complex [55,79]. Considering the increase of oxidative stress and the oxidation of complex I subunits during aging [61,62], the continuous import and exchange of the new-synthesized subunits of peripheral hydrophilic arm with the old oxidized ones could represent a mechanism of scavenger of complex I. The levels of hydrophilic arm subunits of complex I appear to correlate positively with the chaperon function of prohibitin proteins (PHB1 and PHB2). Interestingly, in *C. elegans*, the depletion of PHB increases lifespan in mutants with compromised respiratory chain [80] and, in

cell with a damaged assembly of complex I, the PHB knockdown restores the assembly lowering the complex I-dependent ROS production [80]. All data are consistent with the possible dangerous effect due to the abundant hydrophilic arm subunits of complex I that can assemble to form a sub-complex producing superoxide, without contributing to proton pumping but contributing to age-dependent mitochondrial decline [71]. In this scenario, it would be very interesting to understand if the specific complex I subunits of the hydrophilic arm are mainly involved. In higher eukaryotes, both NDUFV2 and NDUF54, a core and a supernumerary subunits, respectively, have been found to negatively correlate with increased longevity [68], instead, the down-regulation of NDUF52, a core subunit, did not appear to affect longevity [81].

In this regard, evidences have been produced in *C. elegans*, in which the knock-down of complex I subunits affected the lifespan [82,83]. In particular the RNA interference of nuo-2 [82,84], the *C. elegans* homolog of mammalian NADH dehydrogenase iron-sulfur protein 3 (NDUFS3) and D2030.4, the homolog of mammalian NADH dehydrogenase 1 beta subcomplex subunit 7 (NDUFB7) [83] extended lifespan leading to a 50% reduction of the ATP production [82,83]. However, the relationship between electron transport chain function, ROS production and longevity appears to be not so simple. Indeed, the timing of RNAi knockdown is fundamental. For example, the reduced subunit expression during adult stages, after completion of the critical L3/L4 larval stages, caused a reduced ATP level that is not, however, associated with an increase of longevity [82]. Moreover, other studies in *C. elegans* have produced evidence showing that worms with reduced electron transport chain activity, induced by the RNAi knockdown of Nuo-1, orthologous to human NDUFV1, of nuo-6, orthologous to human NDUF54, have extended longevity associated, this time, with an increase of ROS levels [85–87].

Further studies have been carried out in *Drosophila*. In line with those observed in *C. elegans*, the reduced expression of two different complex I subunits in flies such as CG9172, the mammalian NADH dehydrogenase iron-sulfur protein 7 (NDUFS7) and CG9762, the mammalian NADH dehydrogenase 1 beta subcomplex 5 (NDUFB5) caused increased lifespan [88]. However, the knocking down of other complex I subunits in flies showed conflicting results in terms of ATP level [88,89] and longevity [89] not reproducing the results observed in *C. elegans*.

Thus, the attempt to correlate the content of matrix subunits of complex I and the ROS production with longevity is more complicated than expected. Very interestingly, recent findings showed that increasing ROS production, specifically through RET activity at complex I, delays aging and the onset of age-related diseases in flies [90]. In line with this, the suppression of ROS production via RET reduces survival [90]. It has been found that the ROS produced via RET required an uninterrupted electron flow through the electron transport chain that was lost in aged flies [91]. It is important to keep in mind that complex I can assemble together with the complex II, complex III and complex IV to form a supramolecular structure called supercomplex. Of note, the supercomplex formation has been associated with the reduction of complex I-dependent ROS production also via RET [59,92] and a decrease of supercomplex assembly during aging has been observed in mitochondria isolated from the cortex of young (5 months old) and aged (30 months old) Wistar rats [93]. In this scenario, further studies should take in account the ROS production during both forward and reverse electron transfer and the assembly of complex I into supercomplex in order to shed new light on the molecular mechanism of mitochondrial ROS production during aging.

4. cAMP-Dependent Regulation of Mitochondria and ROS Production

cAMP is generated from ATP by adenylyl cyclases (ACs) and degraded by phosphodiesterases. In mammals, there is one gene encoding for multiple isoforms of soluble adenylyl cyclase (sAC) and nine genes encoding for transmembrane adenylyl cyclases (tmAC). tmACs are localized to the plasma membrane, while sAC is present in the mitochondrial matrix and in other organelles [27]. cAMP-dependent protein kinase A (PKA)

is a cAMP downstream effector. It is a tetramer that consists of two cAMP-binding regulatory (R) subunits and two catalytic (C) subunits, which dissociate once cAMP binds R-PKA. R-PKA are associated to sub-cellular membranes by binding to specific A-kinase anchor proteins (AKAP). AKAP protein can also bind phosphatases and also phosphodiesterases [94]. In this way, these complexes accomplish activation/deactivation of the signal and phosphorylation/dephosphorylation of substrate bound or close to the complexes modulating the activity of specific proteins [94]. All these proteins involved in reversible cAMP-dependent protein phosphorylation are also present in mitochondria [27–30].

First evidence on the cytosolic cAMP-dependent regulation of complex I comes from Papa's laboratory showing that the activation of cAMP pathway by widespread addition of a permeant derivative of cAMP (dibutyryl-cAMP or 8-br-cAMP) or by the specific activation of mACh by β -adrenoceptor agonist isoproterenol or by cholera toxin, results, in a variety of murine and human cell cultures, in the elevation of the NADH-ubiquinone oxidoreductase activity of mitochondrial complex I [8,10,55,95]. This was also associated with a strong reduction of the ROS level [10,12,13,55,96]. At the same time, the activation of cAMP signaling did not affect the ROS scavenger systems [13,96]. Thus, the cAMP-dependent decrease of ROS level appears to be associated with changes in the enzymatic activity of complex I. The cAMP-dependent promotion of the complex I activity and decrease ROS production are associated to the serine phosphorylation in the conserved RVS site in the carboxy terminus of the subunit of complex I encoded by the nuclear NDUFS4 gene [95,97]. Further insights have been produced on the molecular mechanism of the cAMP-dependent increase of complex I activity. We showed that PKA-mediated NDUFS4 phosphorylation increases its mitochondrial import [98]. Once in mitochondria, the new-imported NDUFS4 assembles in the complex I by replacing the pre-existing, already assembled, oxidized NDUFS4 subunit restoring the activity of oxidatively damaged complex I [55]. Recently, using ex vivo and in vitro models, it has also been shown that the activation of cAMP/PKA cascade resulted in an increase of supercomplex formation associated with an enhanced capacity of electron flux and ATP production rate [58]. This is also associated with the phosphorylation of the NDUFS4 subunit of complex I [58], and at the same time, the formation of supercomplexes has been associated with the decrease of complex I-dependent ROS production [59,92].

The cAMP signal also impacts the mitochondrial dynamics by different G proteins. Among these, the Drp1 protein is inactivated by its PKA-dependent phosphorylation. The inactivation of Drp1 results in the inhibition of mitochondrial fission and thus in the promotion of fusion [99,100]. At the same time, the activity of the complex I, as well as of the all respiratory chain, is affected by the balance between mitochondrial fusion and fission, indeed, the inhibition of complex I results in mitochondrial fission [99].

Regarding the mitochondrial pool of the cAMP it has, so far, been found that sAC-dependent cAMP production in mitochondria is involved in the regulation of cytochrome *c* oxidase activity, by direct PKA-dependent phosphorylation of complex IV subunits [32], complex I activity, by regulating the degradation of new-imported subunits of peripheral arm [31] including NDUFV2 and NDUFS4 [31], FoF1 ATP synthase activity and its structural organization [33] and ATP production [34], and in the activation of the mitochondrial pathway of apoptosis [35].

In addition to the post-translational processes the cAMP pathway impacts mitochondrial biogenesis responding to neurotransmitters, cell growth factors, hormones and events like exercise and cold adaptation [101–104]. cAMP-response element binding protein (CREB) plays a role in the mitochondrial biogenesis [14,105] by promoting the expression of PGC-1 α (the transcriptional coactivator PPAR γ coactivator 1 α [10,95]). PGC-1 α , in turn activates the expression of the nuclear respiratory transcription factors (NRF1 and NRF2). NRF1 and NRF2 promote the expression of nuclear genes encoding for proteins of the mitochondrial respiratory chain, FoF1-ATP synthase, mitochondrial import system and enzymes of heme biosynthesis [106]. In addition to the nucleus, CREB is also present in the

inner mitochondrial compartment of rat brain where induces the mitochondrially encoded protein synthesis and leads to the increase of complex I-dependent respiration [107–109].

5. cAMP Pathway in Aging

The major complication of normal healthy aging is the increasing risk of age-related diseases [110]. cAMP signaling has been found to be involved in several age-related diseases, such as dementia and metabolic diseases [9,111]. For example, cAMP can impact both insulin and glucagon secretion [112]. Therefore, it is not a surprise that the cAMP pathway also affects diabetes conditions [9]. In this context, it has been proposed that defects of cAMP pathway contribute to the impaired islet cell function in type 2 diabetes [112].

However, although cAMP signaling has been widely studied, little information is available during the aging process. Findings show an altered cAMP signaling associated with physiological brain aging but with conflicting results. Tendentially, in animal brain, a reduction of adenylyl cyclase activity has been found during aging, even if several studies did not reported changes [113–116]. As for cAMP production, the data on basal cAMP levels are also conflicting depending on mammalian tissues: in white blood cells and serum from human and rodents, cAMP levels were lower in aged than young adult [117–120]. The basal level of cAMP decreases also in aged rodent cortex [113,115,121,121], thalamus and hypothalamus [115,122], while no changes has been observed in human cerebral microvessels [123,124] and rodent hippocampus [113,115,122,125] and cerebellum [113,115]. Additionally, the PKA activity has been found decreased in the aged prefrontal cortex, hippocampus and serum of rodents and fly brain with respect to young [120,126,126,127]. However, in aged cerebral microvessels, the PKA activity did not change [128]. As for production, basal level and effector, also the degradation of cAMP in aging are widely variable, depending on the specific isoform of phosphodiesterases (PDE) and tissue but, on the contrary of adenylyl cyclase activity and basal level of cAMP, the total PDE activity tendentially augmented with aging [120,129–134]. Moreover, it has been shown that the cAMP/PKA signaling is differently affected by aging in the hippocampus and frontal cortex of rats and rhesus monkeys [126,135]. In particular, in newborn rat hippocampus, a low PKA activity has been observed which increases in mature and postmature rats and finally declines in old rats. The most studied protein involved in the cAMP signal during aging process is the protein CREB. CREB protein is ubiquitously expressed in all tissues including brain and it is involved in several functions such as cellular growth, memory and neuronal proliferation. CREB expressed in prefrontal and hippocampus region shows alterations during aging [136].

Thus, as general results, even if depending on tissues and species, during aging a decline of cAMP/PKA system appears to occur.

6. cAMP/PKA System and Mitochondria in Aging and Neurodegenerative Diseases

In the last years, an increasing number of studies have attempted to activate cAMP signaling to treat the cognitive decline in age-related diseases associated with mitochondrial dysfunctions and ROS production. This idea comes from a long-line of studies showing a main role of cAMP signal in the memory consolidation mechanism and in the regulation of mitochondrial functions.

cAMP treatment has been reported to extend the lifespan of wild type *Drosophila melanogaster* in mice [137]. In particular, in mice it has been shown that exogenous cAMP improved ageing-related phenotypes by increasing sirtuin 3 (Sirt3) protein levels and reducing oxidative stress [137]. Sirt3 is the major mitochondrial sirtuin that regulates complex I activity and ROS production [138]. cAMP, miming the caloric restriction, can increase the protein level of Sirt3 by binding it and preventing its degradation [137,139].

An example of how a deregulation of the cAMP signal results in detrimental impairment of complex I activity associated with an increase of ROS production has been provided by a study in skin fibroblasts of a Down syndrome patient [24]. Down syndrome, caused by trisomy of chromosome 21, is characterized by mental retardation associated

with premature aging and neurodegeneration. A strong decrease in the basal cAMP level and PKA activity was found in the patient's fibroblasts [140] and this was accompanied by a reduction of phosphorylation of the NDUF54 subunit of complex I, reduced complex I activity and augmented ROS levels [24]. The addition to the cell cultures of dibutyryl-cAMP or epigallocatechin gallate-dependent-activation of the cAMP/PKA pathway rescued all the altered parameters [24].

In sporadic PD a decreased activity of complex I and oxidative damage of its subunits have been found in substantia nigra and dopaminergic neurons of autaptic patients [141]. The involvement of complex I is highlighted by exposure to inhibitors of complex I like in drug abusers, in which the MPP⁺ metabolite of MPTP, which inhibits complex I, causes PD [142] and like the exposure of animal laboratories to rotenone that reproduces the characteristic sporadic PD features [143,144]. In NDUF54 KO mice, resulting in the loss of complex I activity, the dopaminergic neurons are more sensitive to rotenone-induced cell death [143] indicating that defective complex I can be a risk for PD development [143,144]. The mitochondrial dysfunctions have been also observed in familial PD. Mutations of *PARK2* and *PARK6* genes, encoding for parkin and PINK1, respectively, are responsible of the onset of familial PD. Parkin and PINK1 proteins are involved in the mitochondrial quality control pathways in the cells that identifies impaired mitochondria and selectively primes their elimination by mitophagy [145,146]. As for sporadic PD, also in familial PD, a defect of the respiratory chain complex I, decreased ATP production, increased ROS and oxidative stress, and abnormal mitochondrial dynamics have been observed [147–150]. It has been found, in primary skin fibroblasts harboring mutation in the *parkin* gene, that the mitochondrial dysfunctions were associated with altered cAMP level [21]. In addition, neuroblastoma cell lines, with reduced expression of PINK1, displayed mitochondrial fragmentation and reduced respiratory chain capacity [20,63]. These dysfunctions were rescued by cAMP/PKA system activation [20].

In post-mortem samples of brain hippocampal tissues from Alzheimer's patients, the defective expression of phospho-CREB, PGC-1 α , NRF1, NRF2 and mitochondrial transcriptor factor (TFAM) was observed. The same defective expression was observed in APPswe M17 cell line model of Alzheimer diseases and this was rescued by cAMP signal activation in a dose-dependent manner [151]. According to these results, in β -amyloid-treated astrocytes, the activation of cAMP/PKA pathway by glucagon like peptide-1 increased the mitochondrial energy production, the mitochondrial membrane potential and decreased mitochondrial ROS production [26].

Very interestingly, in several neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and progressive forms of multiple sclerosis, sharing some common physio pathological mechanisms including mitochondrial dysfunction and oxidative stress [42,64,152–154], the use of phosphodiesterase inhibitors that increase cAMP level is strongly under investigation [22,155–157].

7. Conclusions

Generally, the aging process in mammals leads to a reduction in genes encoding for the complex I subunits associated with an increase of ROS production (Figure 2).

Indeed, in age-associated diseases such as Parkinson's disease, a reduced expression of complex I subunits has been observed to be linked to a decrease of its activity and an increase of ROS production. However, in lower organisms such as *C. elegans* and *Drosophila*, the decrease of some complex I subunits increases the lifespan and lowers the ROS level. This apparent contradiction could be of note. In fact, in mice, evidences suggest that the hydrophilic arm subunits of complex I can assemble to form a sub-complex producing superoxide without contributing to proton pumping but contributing to age-dependent mitochondrial decline (Figure 2), that means that the increase of this dangerous subcomplex of complex I can favor the aging process. In addition to the role of hydrophilic peripheral complex I subunits, and thus perhaps of a subcomplex, it is worth considering the findings showing that increasing ROS production, specifically through RET activity at complex I,

delays aging and the onset of age-related diseases in flies. Moreover, the supercomplex formation has been associated with the reduction of complex I-dependent ROS production, also via RET and a decrease of supercomplex assembly during aging has been observed (Figure 2).




Figure 2. Several alterations have been found to affect complex I during aging process. A functional decline, associated with a decrease of complex I content, has been observed [60,65]. The complex I-dependent ROS production increases with aging in accordance with the increase of oxidation of complex I subunits [2,5,61,62]. Additionally, the superassembly of complex I has been found decreased during aging [93]. Very interesting, a dangerous effect of the subunits belonging to peripheral hydrophilic arm has been observed. In particular, the peripheral subunits hydrophilic arm can form a subcomplex I that oxidize NADH without the proton pumping but producing ROS [71]. cAMP pathway has been found altered during aging process. The cAMP/PKA cascade promotes complex I activity [8,10,55] by increasing the mitochondrial import of the NDUF54 subunit [98]. Once in mitochondria, the level of the NDUF54 protein, as well as, the other peripheral subunits, is sustained by mitochondrial cAMP pool [31]. This can allow a dynamic exchange between the new imported subunits and the already assembled probably oxidized ones, as found for NDUFV2 and NDUF54 [31,37,55]. The PKA-dependent phosphorylation of the NDUF54 subunit is found associated with the cAMP-dependent increase of complex I assembly in supercomplex [58].

Importantly, all these processes are regulated at post-translational level in mammals. The cAMP signal is one of the most studied second messenger that impinges mitochondrial complex I functions and content and reduces the complex I-ROS production (Figure 2). Therefore, further research on the aging process could also be directed to the effect of cAMP on mitochondrial ROS production in forward and reverse mode, the subassembly of peripheral hydrophilic subunits and the superassembly of complex I in supercomplexes.

Author Contributions: Conceptualization, A.S. and D.D.R.; resources, A.S. and D.D.R.; writing—original draft preparation, A.S. and D.D.R.; writing—review and editing, A.S. and D.D.R.; funding acquisition, A.S. and D.D.R. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded from local funds University of Bari “Aldo Moro”, project title “Regolazione dei sistemi redox e bioenergetici cellulari in condizioni fisio-patologiche” to A.S. and D.D.R., and University of Bari “Aldo Moro”, ex 60%, to A.S.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Papa, S.; De Rasmio, D. Complex I Deficiencies in Neurological Disorders. *Trends Mol. Med.* **2013**, *19*, 61–69. [[CrossRef](#)] [[PubMed](#)]
2. Stefanatos, R.; Sanz, A. The Role of Mitochondrial ROS in the Aging Brain. *FEBS Lett.* **2018**, *592*, 743–758. [[CrossRef](#)] [[PubMed](#)]
3. Wong, H.-S.; Dighe, P.A.; Mezera, V.; Monternier, P.-A.; Brand, M.D. Production of Superoxide and Hydrogen Peroxide from Specific Mitochondrial Sites under Different Bioenergetic Conditions. *J. Biol. Chem.* **2017**, *292*, 16804–16809. [[CrossRef](#)] [[PubMed](#)]
4. Murphy, M.P. How Mitochondria Produce Reactive Oxygen Species. *Biochem. J.* **2009**, *417*, 1–13. [[CrossRef](#)]
5. Barja, G. Towards a Unified Mechanistic Theory of Aging. *Exp. Gerontol.* **2019**, *124*, 110627. [[CrossRef](#)]
6. Ramzan, R.; Kadenbach, B.; Vogt, S. Multiple Mechanisms Regulate Eukaryotic Cytochrome C Oxidase. *Cells* **2021**, *10*, 514. [[CrossRef](#)]
7. Módis, K.; Panopoulos, P.; Coletta, C.; Papapetropoulos, A.; Szabo, C. Hydrogen Sulfide-Mediated Stimulation of Mitochondrial Electron Transport Involves Inhibition of the Mitochondrial Phosphodiesterase 2A, Elevation of cAMP and Activation of Protein Kinase A. *Biochem. Pharm.* **2013**, *86*, 1311–1319. [[CrossRef](#)]
8. Papa, S.; Scacco, S.; De Rasmio, D.; Signorile, A.; Papa, F.; Panelli, D.; Nicastro, A.; Scaringi, R.; Santeramo, A.; Roca, E.; et al. cAMP-Dependent Protein Kinase Regulates Post-Translational Processing and Expression of Complex I Subunits in Mammalian Cells. *Biochim. Et Biophys. Acta* **2010**, *1797*, 649–658. [[CrossRef](#)]
9. Aslam, M.; Ladilov, Y. Emerging Role of cAMP/AMPK Signaling. *Cells* **2022**, *11*, 308. [[CrossRef](#)]
10. De Rasmio, D.; Gattoni, G.; Papa, F.; Santeramo, A.; Pacelli, C.; Cocco, T.; Micelli, L.; Sardaro, N.; Larizza, M.; Scivetti, M.; et al. The β -Adrenoceptor Agonist Isoproterenol Promotes the Activity of Respiratory Chain Complex I and Lowers Cellular Reactive Oxygen Species in Fibroblasts and Heart Myoblasts. *Eur. J. Pharm.* **2011**, *652*, 15–22. [[CrossRef](#)]
11. Papa, S.; Rasmio, D.D.; Technikova-Dobrova, Z.; Panelli, D.; Signorile, A.; Scacco, S.; Petruzzella, V.; Papa, F.; Palmisano, G.; Gnoni, A.; et al. Respiratory Chain Complex I, a Main Regulatory Target of the cAMP/PKA Pathway Is Defective in Different Human Diseases. *FEBS Lett.* **2012**, *586*, 568–577. [[CrossRef](#)] [[PubMed](#)]
12. Raha, S.; Myint, A.T.; Johnstone, L.; Robinson, B.H. Control of Oxygen Free Radical Formation from Mitochondrial Complex I: Roles for Protein Kinase A and Pyruvate Dehydrogenase Kinase. *Free Radic. Biol. Med.* **2002**, *32*, 421–430. [[CrossRef](#)] [[PubMed](#)]
13. Bellomo, F.; Piccoli, C.; Cocco, T.; Scacco, S.; Papa, F.; Gaballo, A.; Boffoli, D.; Signorile, A.; D'Aprile, A.; Scrima, R.; et al. Regulation by the cAMP Cascade of Oxygen Free Radical Balance in Mammalian Cells. *Antioxid Redox Signal.* **2006**, *8*, 495–502. [[CrossRef](#)] [[PubMed](#)]
14. Lin, J.; Handschin, C.; Spiegelman, B.M. Metabolic Control through the PGC-1 Family of Transcription Coactivators. *Cell Metab.* **2005**, *1*, 361–370. [[CrossRef](#)]
15. Elkhoely, A. Liraglutide Ameliorates Gentamicin-Induced Acute Kidney Injury in Rats via PGC-1 α - Mediated Mitochondrial Biogenesis: Involvement of PKA/CREB and Notch/Hes-1 Signaling Pathways. *Int. Immunopharmacol.* **2022**, *114*, 109578. [[CrossRef](#)]
16. Terracina, S.; Petrella, C.; Francati, S.; Lucarelli, M.; Barbato, C.; Minni, A.; Ralli, M.; Greco, A.; Tarani, L.; Fiore, M.; et al. Antioxidant Intervention to Improve Cognition in the Aging Brain: The Example of Hydroxytyrosol and Resveratrol. *Int. J. Mol. Sci.* **2022**, *23*, 15674. [[CrossRef](#)]
17. Park, S.-J.; Ahmad, F.; Philp, A.; Baar, K.; Williams, T.; Luo, H.; Ke, H.; Rehmann, H.; Taussig, R.; Brown, A.L.; et al. Resveratrol Ameliorates Aging-Related Metabolic Phenotypes by Inhibiting cAMP Phosphodiesterases. *Cell* **2012**, *148*, 421–433. [[CrossRef](#)]
18. Signorile, A.; Micelli, L.; De Rasmio, D.; Santeramo, A.; Papa, F.; Ficarella, R.; Gattoni, G.; Scacco, S.; Papa, S. Regulation of the Biogenesis of OXPHOS Complexes in Cell Transition from Replicating to Quiescent State: Involvement of PKA and Effect of Hydroxytyrosol. *Biochim. Biophys. Acta* **2014**, *1843*, 675–684. [[CrossRef](#)]
19. Li, H.; Xu, X.; Cai, M.; Qu, Y.; Ren, Z.; Ye, C.; Shen, H. The Combination of HT-Ac and HBET Improves the Cognitive and Learning Abilities of Heat-Stressed Mice by Maintaining Mitochondrial Function through the PKA-CREB-BDNF Pathway. *Food Funct.* **2022**, *13*, 6166–6179. [[CrossRef](#)]
20. Dagda, R.K.; Gusdon, A.M.; Pien, I.; Strack, S.; Green, S.; Li, C.; Van Houten, B.; Cherra, S.J.; Chu, C.T. Mitochondrially Localized PKA Reverses Mitochondrial Pathology and Dysfunction in a Cellular Model of Parkinson's Disease. *Cell Death Differ.* **2011**, *18*, 1914–1923. [[CrossRef](#)]
21. Signorile, A.; Ferretta, A.; Pacelli, C.; Capitano, N.; Tanzarella, P.; Matrella, M.L.; Valletti, A.; De Rasmio, D.; Cocco, T. Resveratrol Treatment in Human Parkin-Mutant Fibroblasts Modulates cAMP and Calcium Homeostasis Regulating the Expression of Mitochondria-Associated Membranes Resident Proteins. *Biomolecules* **2021**, *11*, 1511. [[CrossRef](#)] [[PubMed](#)]
22. Sanders, O.; Rajagopal, L. Phosphodiesterase Inhibitors for Alzheimer's Disease: A Systematic Review of Clinical Trials and Epidemiology with a Mechanistic Rationale. *J. Alzheimers Dis. Rep.* **2020**, *4*, 185–215. [[CrossRef](#)] [[PubMed](#)]
23. Wiciński, M.; Socha, M.; Malinowski, B.; Wódkiewicz, E.; Walczak, M.; Górski, K.; Słupski, M.; Pawlak-Osińska, K. Liraglutide and Its Neuroprotective Properties-Focus on Possible Biochemical Mechanisms in Alzheimer's Disease and Cerebral Ischemic Events. *Int. J. Mol. Sci.* **2019**, *20*, 1050. [[CrossRef](#)] [[PubMed](#)]

24. Valenti, D.; De Rasmio, D.; Signorile, A.; Rossi, L.; de Bari, L.; Scala, I.; Granese, B.; Papa, S.; Vacca, R.A. Epigallocatechin-3-Gallate Prevents Oxidative Phosphorylation Deficit and Promotes Mitochondrial Biogenesis in Human Cells from Subjects with Down's Syndrome. *Biochim. Biophys. Acta* **2013**, *1832*, 542–552. [[CrossRef](#)]
25. Ferretta, A.; Gaballo, A.; Tanzarella, P.; Piccoli, C.; Capitanio, N.; Nico, B.; Annese, T.; Di Paola, M.; Dell'aquila, C.; De Mari, M.; et al. Effect of Resveratrol on Mitochondrial Function: Implications in Parkin-Associated Familial Parkinson's Disease. *Biochim. Biophys. Acta* **2014**, *1842*, 902–915. [[CrossRef](#)]
26. Xie, Y.; Zheng, J.; Li, S.; Li, H.; Zhou, Y.; Zheng, W.; Zhang, M.; Liu, L.; Chen, Z. GLP-1 Improves the Neuronal Supportive Ability of Astrocytes in Alzheimer's Disease by Regulating Mitochondrial Dysfunction via the CAMP/PKA Pathway. *Biochem. Pharm.* **2021**, *188*, 114578. [[CrossRef](#)]
27. Zippin, J.H.; Chen, Y.; Nahirney, P.; Kamenetsky, M.; Wuttke, M.S.; Fischman, D.A.; Levin, L.R.; Buck, J. Compartmentalization of Bicarbonate-Sensitive Adenylyl Cyclase in Distinct Signaling Microdomains. *FASEB J.* **2003**, *17*, 82–84. [[CrossRef](#)]
28. Signorile, A.; Sardanelli, A.M.; Nuzzi, R.; Papa, S. Serine (Threonine) Phosphatase(s) Acting on CAMP-Dependent Phosphoproteins in Mammalian Mitochondria. *FEBS Lett.* **2002**, *512*, 91–94. [[CrossRef](#)]
29. Sardanelli, A.M.; Signorile, A.; Nuzzi, R.; Rasmio, D.D.; Technikova-Dobrova, Z.; Drahota, Z.; Occhiello, A.; Pica, A.; Papa, S. Occurrence of A-Kinase Anchor Protein and Associated CAMP-Dependent Protein Kinase in the Inner Compartment of Mammalian Mitochondria. *FEBS Lett.* **2006**, *580*, 5690–5696. [[CrossRef](#)]
30. Acin-Perez, R.; Russwurm, M.; Günnewig, K.; Gertz, M.; Zoidl, G.; Ramos, L.; Buck, J.; Levin, L.R.; Rassow, J.; Manfredi, G.; et al. A Phosphodiesterase 2A Isoform Localized to Mitochondria Regulates Respiration. *J. Biol. Chem.* **2011**, *286*, 30423–30432. [[CrossRef](#)]
31. De Rasmio, D.; Signorile, A.; Santeramo, A.; Larizza, M.; Lattanzio, P.; Capitanio, G.; Papa, S. Intramitochondrial Adenylyl Cyclase Controls the Turnover of Nuclear-Encoded Subunits and Activity of Mammalian Complex I of the Respiratory Chain. *Biochim. Biophys. Acta* **2015**, *1853*, 183–191. [[CrossRef](#)] [[PubMed](#)]
32. Acin-Perez, R.; Salazar, E.; Kamenetsky, M.; Buck, J.; Levin, L.R.; Manfredi, G. Cyclic AMP Produced inside Mitochondria Regulates Oxidative Phosphorylation. *Cell Metab.* **2009**, *9*, 265–276. [[CrossRef](#)] [[PubMed](#)]
33. De Rasmio, D.; Micelli, L.; Santeramo, A.; Signorile, A.; Lattanzio, P.; Papa, S. CAMP Regulates the Functional Activity, Coupling Efficiency and Structural Organization of Mammalian FOF1 ATP Synthase. *Biochim. Biophys. Acta* **2016**, *1857*, 350–358. [[CrossRef](#)] [[PubMed](#)]
34. Di Benedetto, G.; Scalzotto, E.; Mongillo, M.; Pozzan, T. Mitochondrial Ca²⁺ Uptake Induces Cyclic AMP Generation in the Matrix and Modulates Organelle ATP Levels. *Cell Metab.* **2013**, *17*, 965–975. [[CrossRef](#)]
35. Kumar, S.; Kostin, S.; Flacke, J.-P.; Reusch, H.P.; Ladilov, Y. Soluble Adenylyl Cyclase Controls Mitochondria-Dependent Apoptosis in Coronary Endothelial Cells. *J. Biol. Chem.* **2009**, *284*, 14760–14768. [[CrossRef](#)]
36. Carroll, J.; Fearnley, I.M.; Skehel, J.M.; Shannon, R.J.; Hirst, J.; Walker, J.E. Bovine Complex I Is a Complex of 45 Different Subunits. *J. Biol. Chem.* **2006**, *281*, 32724–32727. [[CrossRef](#)] [[PubMed](#)]
37. Lazarou, M.; Thorburn, D.R.; Ryan, M.T.; McKenzie, M. Assembly of Mitochondrial Complex I and Defects in Disease. *Biochim. Biophys. Acta* **2009**, *1793*, 78–88. [[CrossRef](#)]
38. Cortés-Rojo, C.; Vargas-Vargas, M.A.; Olmos-Orizaba, B.E.; Rodríguez-Orozco, A.R.; Calderón-Cortés, E. Interplay between NADH Oxidation by Complex I, Glutathione Redox State and Sirtuin-3, and Its Role in the Development of Insulin Resistance. *Biochim. Biophys. Acta Mol. Basis Dis.* **2020**, *1866*, 165801. [[CrossRef](#)]
39. Kong, D.; Zhao, L.; Du, Y.; He, P.; Zou, Y.; Yang, L.; Sun, L.; Wang, H.; Xu, D.; Meng, X.; et al. Overexpression of GRIM-19, a Mitochondrial Respiratory Chain Complex I Protein, Suppresses Hepatocellular Carcinoma Growth. *Int. J. Clin. Exp. Pathol.* **2014**, *7*, 7497–7507.
40. Ricci, J.-E.; Muñoz-Pinedo, C.; Fitzgerald, P.; Bailly-Maitre, B.; Perkins, G.A.; Yadava, N.; Scheffler, I.E.; Ellisman, M.H.; Green, D.R. Disruption of Mitochondrial Function during Apoptosis Is Mediated by Caspase Cleavage of the P75 Subunit of Complex I of the Electron Transport Chain. *Cell* **2004**, *117*, 773–786. [[CrossRef](#)]
41. Balaban, R.S.; Nemoto, S.; Finkel, T. Mitochondria, Oxidants, and Aging. *Cell* **2005**, *120*, 483–495. [[CrossRef](#)] [[PubMed](#)]
42. Monzio Compagnoni, G.; Di Fonzo, A.; Corti, S.; Comi, G.P.; Bresolin, N.; Masliah, E. The Role of Mitochondria in Neurodegenerative Diseases: The Lesson from Alzheimer's Disease and Parkinson's Disease. *Mol. Neurobiol.* **2020**, *57*, 2959–2980. [[CrossRef](#)] [[PubMed](#)]
43. Sollazzo, M.; De Luise, M.; Lemma, S.; Bressi, L.; Iorio, M.; Miglietta, S.; Milioni, S.; Kurelac, I.; Iommarini, L.; Gasparre, G.; et al. Respiratory Complex I Dysfunction in Cancer: From a Maze of Cellular Adaptive Responses to Potential Therapeutic Strategies. *FEBS J.* **2022**, *289*, 8003–8019. [[CrossRef](#)] [[PubMed](#)]
44. Efremov, R.G.; Baradaran, R.; Sazanov, L.A. The Architecture of Respiratory Complex I. *Nature* **2010**, *465*, 441–445. [[CrossRef](#)]
45. Brandt, U. Energy Converting NADH:Quinone Oxidoreductase (Complex I). *Annu. Rev. Biochem.* **2006**, *75*, 69–92. [[CrossRef](#)]
46. Cadenas, E.; Davies, K.J. Mitochondrial Free Radical Generation, Oxidative Stress, and Aging. *Free Radic. Biol. Med.* **2000**, *29*, 222–230. [[CrossRef](#)]
47. Fato, R.; Bergamini, C.; Bortolus, M.; Maniero, A.L.; Leoni, S.; Ohnishi, T.; Lenaz, G. Differential Effects of Mitochondrial Complex I Inhibitors on Production of Reactive Oxygen Species. *Biochim. Biophys. Acta* **2009**, *1787*, 384–392. [[CrossRef](#)]
48. Galkin, A.; Brandt, U. Superoxide Radical Formation by Pure Complex I (NADH:Ubiquinone Oxidoreductase) from *Yarrowia Lipolytica*. *J. Biol. Chem.* **2005**, *280*, 30129–30135. [[CrossRef](#)]

49. Lambert, A.J.; Buckingham, J.A.; Boysen, H.M.; Brand, M.D. Diphenyleneiodonium Acutely Inhibits Reactive Oxygen Species Production by Mitochondrial Complex I during Reverse, but Not Forward Electron Transport. *Biochim. Biophys. Acta* **2008**, *1777*, 397–403. [[CrossRef](#)]
50. Lambert, A.J.; Brand, M.D. Inhibitors of the Quinone-Binding Site Allow Rapid Superoxide Production from Mitochondrial NADH:Ubiquinone Oxidoreductase (Complex I). *J. Biol. Chem.* **2004**, *279*, 39414–39420. [[CrossRef](#)]
51. Lenaz, G.; Fato, R.; Genova, M.L.; Bergamini, C.; Bianchi, C.; Biondi, A. Mitochondrial Complex I: Structural and Functional Aspects. *Biochim. Biophys. Acta* **2006**, *1757*, 1406–1420. [[CrossRef](#)] [[PubMed](#)]
52. Pryde, K.R.; Hirst, J. Superoxide Is Produced by the Reduced Flavin in Mitochondrial Complex I: A Single, Unified Mechanism That Applies during Both Forward and Reverse Electron Transfer. *J. Biol. Chem.* **2011**, *286*, 18056–18065. [[CrossRef](#)] [[PubMed](#)]
53. Papa, S.; De Rasmio, D.; Scacco, S.; Signorile, A.; Technikova-Dobrova, Z.; Palmisano, G.; Sardanelli, A.M.; Papa, F.; Panelli, D.; Scaringi, R.; et al. Mammalian Complex I: A Regulable and Vulnerable Pacemaker in Mitochondrial Respiratory Function. *Biochim. Biophys. Acta* **2008**, *1777*, 719–728. [[CrossRef](#)] [[PubMed](#)]
54. Cocco, T.; Pacelli, C.; Sgobbo, P.; Villani, G. Control of OXPHOS Efficiency by Complex I in Brain Mitochondria. *Neurobiol. Aging* **2009**, *30*, 622–629. [[CrossRef](#)]
55. De Rasmio, D.; Signorile, A.; Larizza, M.; Pacelli, C.; Cocco, T.; Papa, S. Activation of the CAMP Cascade in Human Fibroblast Cultures Rescues the Activity of Oxidatively Damaged Complex I. *Free Radic. Biol. Med.* **2012**, *52*, 757–764. [[CrossRef](#)]
56. Gonzalez-Franquesa, A.; Stocks, B.; Chubanava, S.; Hattel, H.B.; Moreno-Justicia, R.; Peijs, L.; Trebak, J.T.; Zierath, J.R.; Deshmukh, A.S. Mass-Spectrometry-Based Proteomics Reveals Mitochondrial Supercomplexome Plasticity. *Cell Rep.* **2021**, *35*, 109180. [[CrossRef](#)]
57. Guarás, A.; Perales-Clemente, E.; Calvo, E.; Acín-Pérez, R.; Loureiro-Lopez, M.; Pujol, C.; Martínez-Carrascoso, I.; Nuñez, E.; García-Marqués, F.; Rodríguez-Hernández, M.A.; et al. The CoQH2/CoQ Ratio Serves as a Sensor of Respiratory Chain Efficiency. *Cell Rep.* **2016**, *15*, 197–209. [[CrossRef](#)]
58. Signorile, A.; Pacelli, C.; Palese, L.L.; Santeramo, A.; Roca, E.; Cocco, T.; De Rasmio, D. CAMP/PKA Signaling Modulates Mitochondrial Supercomplex Organization. *Int. J. Mol. Sci.* **2022**, *23*, 9655. [[CrossRef](#)]
59. Lopez-Fabuel, I.; Le Douce, J.; Logan, A.; James, A.M.; Bonvento, G.; Murphy, M.P.; Almeida, A.; Bolaños, J.P. Complex I Assembly into Supercomplexes Determines Differential Mitochondrial ROS Production in Neurons and Astrocytes. *Proc. Natl. Acad. Sci. USA* **2016**, *113*, 13063–13068. [[CrossRef](#)]
60. Boffoli, D.; Scacco, S.C.; Vergari, R.; Solarino, G.; Santacrose, G.; Papa, S. Decline with Age of the Respiratory Chain Activity in Human Skeletal Muscle. *Biochim. Biophys. Acta* **1994**, *1226*, 73–82. [[CrossRef](#)]
61. Choksi, K.B.; Boylston, W.H.; Rabek, J.P.; Widger, W.R.; Papaconstantinou, J. Oxidatively Damaged Proteins of Heart Mitochondrial Electron Transport Complexes. *Biochim. Biophys. Acta* **2004**, *1688*, 95–101. [[CrossRef](#)] [[PubMed](#)]
62. Choksi, K.B.; Nuss, J.E.; Deford, J.H.; Papaconstantinou, J. Age-Related Alterations in Oxidatively Damaged Proteins of Mouse Skeletal Muscle Mitochondrial Electron Transport Chain Complexes. *Free Radic. Biol. Med.* **2008**, *45*, 826–838. [[CrossRef](#)] [[PubMed](#)]
63. Morais, V.A.; Verstrecken, P.; Roethig, A.; Smet, J.; Snellinx, A.; Vanbrabant, M.; Haddad, D.; Frezza, C.; Mandemakers, W.; Vogt-Weisenhorn, D.; et al. Parkinson's Disease Mutations in PINK1 Result in Decreased Complex I Activity and Deficient Synaptic Function. *EMBO Mol. Med.* **2009**, *1*, 99–111. [[CrossRef](#)] [[PubMed](#)]
64. Keeney, P.M.; Xie, J.; Capaldi, R.A.; Bennett, J.P. Parkinson's Disease Brain Mitochondrial Complex I Has Oxidatively Damaged Subunits and Is Functionally Impaired and Misassembled. *J. Neurosci.* **2006**, *26*, 5256–5264. [[CrossRef](#)] [[PubMed](#)]
65. Pamplona, R.; Jové, M.; Mota-Martorell, N.; Barja, G. Is the NDUFV2 Subunit of the Hydrophilic Complex I Domain a Key Determinant of Animal Longevity? *FEBS J.* **2021**, *288*, 6652–6673. [[CrossRef](#)]
66. Ku, H.H.; Sohal, R.S. Comparison of Mitochondrial Pro-Oxidant Generation and Anti-Oxidant Defenses between Rat and Pigeon: Possible Basis of Variation in Longevity and Metabolic Potential. *Mech. Ageing Dev.* **1993**, *72*, 67–76. [[CrossRef](#)]
67. Ku, H.H.; Brunk, U.T.; Sohal, R.S. Relationship between Mitochondrial Superoxide and Hydrogen Peroxide Production and Longevity of Mammalian Species. *Free Radic. Biol. Med.* **1993**, *15*, 621–627. [[CrossRef](#)]
68. Mota-Martorell, N.; Jové, M.; Pradas, I.; Sanchez, I.; Gómez, J.; Naudi, A.; Barja, G.; Pamplona, R. Low Abundance of NDUFV2 and NDUF4 Subunits of the Hydrophilic Complex I Domain and VDAC1 Predicts Mammalian Longevity. *Redox Biol.* **2020**, *34*, 101539. [[CrossRef](#)]
69. Pamplona, R.; Barja, G. Highly Resistant Macromolecular Components and Low Rate of Generation of Endogenous Damage: Two Key Traits of Longevity. *Ageing Res. Rev.* **2007**, *6*, 189–210. [[CrossRef](#)]
70. Jové, M.; Mota-Martorell, N.; Pradas, I.; Galo-Licon, J.D.; Martín-Gari, M.; Obis, È.; Sol, J.; Pamplona, R. The Lipidome Fingerprint of Longevity. *Molecules* **2020**, *25*, 4343. [[CrossRef](#)]
71. Miwa, S.; Jow, H.; Baty, K.; Johnson, A.; Czapiewski, R.; Saretzki, G.; Treumann, A.; von Zglinicki, T. Low Abundance of the Matrix Arm of Complex I in Mitochondria Predicts Longevity in Mice. *Nat. Commun.* **2014**, *5*, 3837. [[CrossRef](#)] [[PubMed](#)]
72. Pamplona, R.; Barja, G. Mitochondrial Oxidative Stress, Aging and Caloric Restriction: The Protein and Methionine Connection. *Biochim. Biophys. Acta* **2006**, *1757*, 496–508. [[CrossRef](#)] [[PubMed](#)]
73. Glossmann, H.H.; Lutz, O.M.D. Metformin and Aging: A Review. *Gerontology* **2019**, *65*, 581–590. [[CrossRef](#)] [[PubMed](#)]

74. Martínez-Cisuelo, V.; Gómez, J.; García-Junceda, I.; Naudí, A.; Cabré, R.; Mota-Martorell, N.; López-Torres, M.; González-Sánchez, M.; Pamplona, R.; Barja, G. Rapamycin Reverses Age-Related Increases in Mitochondrial ROS Production at Complex I, Oxidative Stress, Accumulation of MtDNA Fragments inside Nuclear DNA, and Lipofuscin Level, and Increases Autophagy, in the Liver of Middle-Aged Mice. *Exp. Gerontol.* **2016**, *83*, 130–138. [[CrossRef](#)] [[PubMed](#)]
75. Jovanović, D.Š.; Dorđević, M.; Savković, U.; Lazarević, J. The Effect of Mitochondrial Complex I Inhibitor on Longevity of Short-Lived and Long-Lived Seed Beetles and Its Mitonuclear Hybrids. *Biogerontology* **2014**, *15*, 487–501. [[CrossRef](#)]
76. Barja, G.; Herrero, A. Oxidative Damage to Mitochondrial DNA Is Inversely Related to Maximum Life Span in the Heart and Brain of Mammals. *FASEB J.* **2000**, *14*, 312–318. [[CrossRef](#)]
77. Kim, T.-Y.; Wang, D.; Kim, A.K.; Lau, E.; Lin, A.J.; Liem, D.A.; Zhang, J.; Zong, N.C.; Lam, M.P.Y.; Ping, P. Metabolic Labeling Reveals Proteome Dynamics of Mouse Mitochondria. *Mol. Cell Proteom.* **2012**, *11*, 1586–1594. [[CrossRef](#)]
78. Dieteren, C.E.J.; Koopman, W.J.H.; Swarts, H.G.; Peters, J.G.P.; Maczuga, P.; van Gemst, J.J.; Masereeuw, R.; Smeitink, J.A.M.; Nijtmans, L.G.J.; Willems, P.H.G.M. Subunit-Specific Incorporation Efficiency and Kinetics in Mitochondrial Complex I Homeostasis. *J. Biol. Chem.* **2012**, *287*, 41851–41860. [[CrossRef](#)]
79. Lazarou, M.; McKenzie, M.; Ohtake, A.; Thorburn, D.R.; Ryan, M.T. Analysis of the Assembly Profiles for Mitochondrial- and Nuclear-DNA-Encoded Subunits into Complex I. *Mol. Cell Biol.* **2007**, *27*, 4228–4237. [[CrossRef](#)]
80. Artal-Sanz, M.; Tavernarakis, N. Prohibitin Couples Diapause Signalling to Mitochondrial Metabolism during Ageing in *C. elegans*. *Nature* **2009**, *461*, 793–797. [[CrossRef](#)]
81. McElroy, G.S.; Chakrabarty, R.P.; D'Alessandro, K.B.; Hu, Y.-S.; Vasani, K.; Tan, J.; Stoolman, J.S.; Weinberg, S.E.; Steinert, E.M.; Reyfman, P.A.; et al. Reduced Expression of Mitochondrial Complex I Subunit Ndufs2 Does Not Impact Healthspan in Mice. *Sci. Rep.* **2022**, *12*, 5196. [[CrossRef](#)] [[PubMed](#)]
82. Dillin, A.; Hsu, A.-L.; Arantes-Oliveira, N.; Lehrer-Graiwer, J.; Hsin, H.; Fraser, A.G.; Kamath, R.S.; Ahringer, J.; Kenyon, C. Rates of Behavior and Aging Specified by Mitochondrial Function during Development. *Science* **2002**, *298*, 2398–2401. [[CrossRef](#)] [[PubMed](#)]
83. Lee, S.S.; Lee, R.Y.N.; Fraser, A.G.; Kamath, R.S.; Ahringer, J.; Ruvkun, G. A Systematic RNAi Screen Identifies a Critical Role for Mitochondria in *C. elegans* Longevity. *Nat. Genet.* **2003**, *33*, 40–48. [[CrossRef](#)] [[PubMed](#)]
84. Rea, S.L.; Ventura, N.; Johnson, T.E. Relationship between Mitochondrial Electron Transport Chain Dysfunction, Development, and Life Extension in *Caenorhabditis Elegans*. *PLoS Biol.* **2007**, *5*, e259. [[CrossRef](#)] [[PubMed](#)]
85. Lee, S.-J.; Hwang, A.B.; Kenyon, C. Inhibition of Respiration Extends *C. elegans* Life Span via Reactive Oxygen Species That Increase HIF-1 Activity. *Curr. Biol.* **2010**, *20*, 2131–2136. [[CrossRef](#)] [[PubMed](#)]
86. Yang, W.; Hekimi, S. A Mitochondrial Superoxide Signal Triggers Increased Longevity in *Caenorhabditis Elegans*. *PLoS Biol.* **2010**, *8*, e1000556. [[CrossRef](#)]
87. Yee, C.; Yang, W.; Hekimi, S. The Intrinsic Apoptosis Pathway Mediates the Pro-Longevity Response to Mitochondrial ROS in *C. elegans*. *Cell* **2014**, *157*, 897–909. [[CrossRef](#)]
88. Copeland, J.M.; Cho, J.; Lo, T.; Hur, J.H.; Bahadorani, S.; Arabyan, T.; Rabie, J.; Soh, J.; Walker, D.W. Extension of *Drosophila* Life Span by RNAi of the Mitochondrial Respiratory Chain. *Curr. Biol.* **2009**, *19*, 1591–1598. [[CrossRef](#)]
89. Rera, M.; Monnier, V.; Tricoire, H. Mitochondrial Electron Transport Chain Dysfunction during Development Does Not Extend Lifespan in *Drosophila Melanogaster*. *Mech. Ageing Dev.* **2010**, *131*, 156–164. [[CrossRef](#)]
90. Scialò, F.; Sriram, A.; Fernández-Ayala, D.; Gubina, N.; Löhmus, M.; Nelson, G.; Logan, A.; Cooper, H.M.; Navas, P.; Enríquez, J.A.; et al. Mitochondrial ROS Produced via Reverse Electron Transport Extend Animal Lifespan. *Cell Metab.* **2016**, *23*, 725–734. [[CrossRef](#)]
91. Graham, C.; Stefanatos, R.; Yek, A.E.H.; Spriggs, R.V.; Loh, S.H.Y.; Uribe, A.H.; Zhang, T.; Martins, L.M.; Maddocks, O.D.K.; Scialò, F.; et al. Mitochondrial ROS Signalling Requires Uninterrupted Electron Flow and Is Lost during Ageing in Flies. *Geroscience* **2022**, *44*, 1961–1974. [[CrossRef](#)] [[PubMed](#)]
92. Calvo, E.; Cogliati, S.; Hernansanz-Agustín, P.; Loureiro-López, M.; Guarás, A.; Casuso, R.A.; García-Marqués, F.; Acín-Pérez, R.; Martí-Mateos, Y.; Silla-Castro, J.C.; et al. Functional Role of Respiratory Supercomplexes in Mice: SCAF1 Relevance and Segmentation of the Qpool. *Sci. Adv.* **2020**, *6*, eaba7509. [[CrossRef](#)] [[PubMed](#)]
93. Frenzel, M.; Rommelspacher, H.; Sugawa, M.D.; Dencher, N.A. Ageing Alters the Supramolecular Architecture of OxPhos Complexes in Rat Brain Cortex. *Exp. Gerontol.* **2010**, *45*, 563–572. [[CrossRef](#)] [[PubMed](#)]
94. Wong, W.; Scott, J.D. AKAP Signalling Complexes: Focal Points in Space and Time. *Nat. Rev. Mol. Cell Biol.* **2004**, *5*, 959–970. [[CrossRef](#)]
95. Papa, S.; Scacco, S.; Sardanelli, A.M.; Vergari, R.; Papa, F.; Budde, S.; van den Heuvel, L.; Smeitink, J. Mutation in the NDUF54 Gene of Complex I Abolishes CAMP-Dependent Activation of the Complex in a Child with Fatal Neurological Syndrome. *FEBS Lett.* **2001**, *489*, 259–262. [[CrossRef](#)]
96. Piccoli, C.; Scacco, S.; Bellomo, F.; Signorile, A.; Iuso, A.; Boffoli, D.; Scrima, R.; Capitanio, N.; Papa, S. CAMP Controls Oxygen Metabolism in Mammalian Cells. *FEBS Lett.* **2006**, *580*, 4539–4543. [[CrossRef](#)]
97. De Rasmio, D.; Palmisano, G.; Scacco, S.; Technikova-Dobrova, Z.; Panelli, D.; Cocco, T.; Sardanelli, A.M.; Gnoni, A.; Micelli, L.; Trani, A.; et al. Phosphorylation Pattern of the NDUF54 Subunit of Complex I of the Mammalian Respiratory Chain. *Mitochondrion* **2010**, *10*, 464–471. [[CrossRef](#)]

98. De Rasmio, D.; Panelli, D.; Sardanelli, A.M.; Papa, S. CAMP-Dependent Protein Kinase Regulates the Mitochondrial Import of the Nuclear Encoded NDUFS4 Subunit of Complex I. *Cell Signal.* **2008**, *20*, 989–997. [[CrossRef](#)]
99. Morán, M.; Rivera, H.; Sánchez-Aragó, M.; Blázquez, A.; Merinero, B.; Ugalde, C.; Arenas, J.; Cuezva, J.M.; Martín, M.A. Mitochondrial Bioenergetics and Dynamics Interplay in Complex I-Deficient Fibroblasts. *Biochim. Biophys. Acta* **2010**, *1802*, 443–453. [[CrossRef](#)]
100. Valenti, D.; Rossi, L.; Marzulli, D.; Bellomo, F.; De Rasmio, D.; Signorile, A.; Vacca, R.A. Inhibition of Drp1-Mediated Mitochondrial Fission Improves Mitochondrial Dynamics and Bioenergetics Stimulating Neurogenesis in Hippocampal Progenitor Cells from a Down Syndrome Mouse Model. *Biochim. Biophys. Acta Mol. Basis Dis.* **2017**, *1863*, 3117–3127. [[CrossRef](#)]
101. Herzig, R.P.; Scacco, S.; Scarpulla, R.C. Sequential Serum-Dependent Activation of CREB and NRF-1 Leads to Enhanced Mitochondrial Respiration through the Induction of Cytochrome c. *J. Biol. Chem.* **2000**, *275*, 13134–13141. [[CrossRef](#)] [[PubMed](#)]
102. Nisoli, E.; Clementi, E.; Paolucci, C.; Cozzi, V.; Tonello, C.; Sciorati, C.; Bracale, R.; Valerio, A.; Francolini, M.; Moncada, S.; et al. Mitochondrial Biogenesis in Mammals: The Role of Endogenous Nitric Oxide. *Science* **2003**, *299*, 896–899. [[CrossRef](#)]
103. Wu, H.; Kanatous, S.B.; Thurmond, F.A.; Gallardo, T.; Isotani, E.; Bassel-Duby, R.; Williams, R.S. Regulation of Mitochondrial Biogenesis in Skeletal Muscle by CaMK. *Science* **2002**, *296*, 349–352. [[CrossRef](#)] [[PubMed](#)]
104. Wu, Z.; Huang, X.; Feng, Y.; Handschin, C.; Feng, Y.; Gullicksen, P.S.; Bare, O.; Labow, M.; Spiegelman, B.; Stevenson, S.C. Transducer of Regulated CREB-Binding Proteins (TORCs) Induce PGC-1alpha Transcription and Mitochondrial Biogenesis in Muscle Cells. *Proc. Natl. Acad. Sci. USA* **2006**, *103*, 14379–14384. [[CrossRef](#)] [[PubMed](#)]
105. De Rasmio, D.; Signorile, A.; Papa, F.; Roca, E.; Papa, S. CAMP/Ca²⁺ Response Element-Binding Protein Plays a Central Role in the Biogenesis of Respiratory Chain Proteins in Mammalian Cells. *IUBMB Life* **2010**, *62*, 447–452. [[CrossRef](#)] [[PubMed](#)]
106. Kelly, D.P.; Scarpulla, R.C. Transcriptional Regulatory Circuits Controlling Mitochondrial Biogenesis and Function. *Genes Dev.* **2004**, *18*, 357–368. [[CrossRef](#)]
107. De Rasmio, D.; Signorile, A.; Roca, E.; Papa, S. CAMP Response Element-Binding Protein (CREB) Is Imported into Mitochondria and Promotes Protein Synthesis. *FEBS J.* **2009**, *276*, 4325–4333. [[CrossRef](#)]
108. Ryu, H.; Lee, J.; Impey, S.; Ratan, R.R.; Ferrante, R.J. Antioxidants Modulate Mitochondrial PKA and Increase CREB Binding to D-Loop DNA of the Mitochondrial Genome in Neurons. *Proc. Natl. Acad. Sci. USA* **2005**, *102*, 13915–13920. [[CrossRef](#)]
109. Lee, J.; Kim, C.-H.; Simon, D.K.; Aminova, L.R.; Andreyev, A.Y.; Kushnareva, Y.E.; Murphy, A.N.; Lonze, B.E.; Kim, K.-S.; Ginty, D.D.; et al. Mitochondrial Cyclic AMP Response Element-Binding Protein (CREB) Mediates Mitochondrial Gene Expression and Neuronal Survival. *J. Biol. Chem.* **2005**, *280*, 40398–40401. [[CrossRef](#)]
110. Calabrese, V.; Dattilo, S.; Petralia, A.; Parenti, R.; Pennisi, M.; Koverech, G.; Calabrese, V.; Graziano, A.; Monte, I.; Maiolino, L.; et al. Analytical Approaches to the Diagnosis and Treatment of Aging and Aging-Related Disease: Redox Status and Proteomics. *Free Radic. Res.* **2015**, *49*, 511–524. [[CrossRef](#)]
111. Barcena, M.L.; Aslam, M.; Pozdniakova, S.; Norman, K.; Ladilov, Y. Cardiovascular Inflammaging: Mechanisms and Translational Aspects. *Cells* **2022**, *11*, 1010. [[CrossRef](#)] [[PubMed](#)]
112. Tengholm, A.; Gylfe, E. CAMP Signalling in Insulin and Glucagon Secretion. *Diabetes Obes. Metab.* **2017**, *19*, 42–53. [[CrossRef](#)] [[PubMed](#)]
113. Hara, H.; Onodera, H.; Kato, H.; Kogure, K. Effects of Aging on Signal Transmission and Transduction Systems in the Gerbil Brain: Morphological and Autoradiographic Study. *Neuroscience* **1992**, *46*, 475–488. [[CrossRef](#)]
114. Sugawa, M.; May, T. Age-Related Alteration in Signal Transduction: Involvement of the CAMP Cascade. *Brain Res.* **1993**, *618*, 57–62. [[CrossRef](#)]
115. Puri, S.K.; Volicer, L. Age-Related Changes of Cyclic Nucleotide Levels in Rat Brain Regions. *Mech. Ageing Dev.* **1981**, *15*, 239–242. [[CrossRef](#)] [[PubMed](#)]
116. Makman, M.H.; Ahn, H.S.; Thal, L.J.; Sharpless, N.S.; Dvorkin, B.; Horowitz, S.G.; Rosenfeld, M. Evidence for Selective Loss of Brain Dopamine- and Histamine-Stimulated Adenylate Cyclase Activities in Rabbits with Aging. *Brain Res.* **1980**, *192*, 177–183. [[CrossRef](#)] [[PubMed](#)]
117. Tam, C.F.; Walford, R.L. Alterations in Cyclic Nucleotides and Cyclase-Specific Activities in T Lymphocytes of Aging Normal Humans and Patients with Down's Syndrome. *J. Immunol.* **1980**, *125*, 1665–1670. [[CrossRef](#)]
118. Birkenfeld, A.; Ben Zvi, A. Age Associated Changes in Intracellular Adenosine Monophosphate. *Clin. Exp. Immunol.* **1984**, *55*, 651–654.
119. Fulop, T.; Kekessy, D.; Foris, G. Altered Post-Receptorial Signal Transduction Mechanism under Various Stimulation in Polymorphonuclear Granulocytes of Alzheimer's Disease. *Mech. Ageing Dev.* **1990**, *52*, 277–285. [[CrossRef](#)]
120. Hu, R.; Yuan, B.; Wei, X.; Zhao, L.; Tang, J.; Chen, D. Enhanced CAMP/PKA Pathway by Seabuckthorn Fatty Acids in Aged Rats. *J. Ethnopharmacol.* **2007**, *111*, 248–254. [[CrossRef](#)]
121. Berg, A.; Zimmerman, I.D. Effects of Electrical Stimulation and Norepinephrine on Cyclic-AMP Levels in the Cerebral Cortex of the Aging Rat. *Mech. Ageing Dev.* **1975**, *4*, 377–383. [[CrossRef](#)] [[PubMed](#)]
122. Titus, D.J.; Furones, C.; Kang, Y.; Atkins, C.M. Age-Dependent Alterations in CAMP Signaling Contribute to Synaptic Plasticity Deficits Following Traumatic Brain Injury. *Neuroscience* **2013**, *231*, 182–194. [[CrossRef](#)]
123. Grammas, P.; Roher, A.E.; Ball, M.J. Increased Accumulation of CAMP in Cerebral Microvessels in Alzheimer's Disease. *Neurobiol. Aging* **1994**, *15*, 113–116. [[CrossRef](#)]

124. Martinez, M.; Hernández, A.I.; Hernanz, A. Increased CAMP Immunostaining in Cerebral Vessels in Alzheimer's Disease. *Brain Res.* **2001**, *922*, 148–152. [[CrossRef](#)] [[PubMed](#)]
125. Schmidt, M.J.; Thornberry, J.F. Cyclic AMP and Cyclic GMP Accumulation in Vitro in Brain Regions of Young, Old and Aged Rats. *Brain Res.* **1978**, *139*, 169–177. [[CrossRef](#)] [[PubMed](#)]
126. Karege, F.; Lamercy, C.; Schwald, M.; Steimer, T.; Cissé, M. Differential Changes of CAMP-Dependent Protein Kinase Activity and 3H-CAMP Binding Sites in Rat Hippocampus during Maturation and Aging. *Neurosci. Lett.* **2001**, *315*, 89–92. [[CrossRef](#)] [[PubMed](#)]
127. Laviada, I.D.; Galve-Roperh, I.; Malpartida, J.M.; Haro, A. CAMP Signalling Mechanisms with Aging in the Ceratitit Capitata Brain. *Mech. Ageing Dev.* **1997**, *97*, 45–53. [[CrossRef](#)] [[PubMed](#)]
128. Cashman, R.E.; Grammas, P. CAMP-Dependent Protein Kinase in Cerebral Microvessels in Aging and Alzheimer Disease. *Mol. Chem. Neuropathol.* **1995**, *26*, 247–258. [[CrossRef](#)]
129. Stancheva, S.L.; Alova, L.G. Age-Related Changes of Cyclic AMP Phosphodiesterase Activity in Rat Brain Regions and a New Phosphodiesterase Inhibitor—Nootropic Agent Adafenoxate. *Gen. Pharmacol. Vasc. Syst.* **1991**, *22*, 955–958. [[CrossRef](#)]
130. Chalimoniuk, M.; Strosznajder, J.B. Aging Modulates Nitric Oxide Synthesis and CGMP Levels in Hippocampus and Cerebellum: Effects of Amyloid β Peptide. *Mol. Chem. Neuropathol.* **1998**, *35*, 77–95. [[CrossRef](#)]
131. Kelly, M.P.; Adamowicz, W.; Bove, S.; Hartman, A.J.; Mariga, A.; Pathak, G.; Reinhart, V.; Romegialli, A.; Kleiman, R.J. Select 3',5'-Cyclic Nucleotide Phosphodiesterases Exhibit Altered Expression in the Aged Rodent Brain. *Cell. Signal.* **2014**, *26*, 383–397. [[CrossRef](#)] [[PubMed](#)]
132. Kelly, M.P. Putting Together The Pieces of Phosphodiesterase Distribution Patterns In The Brain: A Jigsaw Puzzle of Cyclic Nucleotide Regulation. In *Cyclic-Nucleotide Phosphodiesterases in the Central Nervous System*; John Wiley & Sons, Ltd.: Hoboken, NJ, USA, 2014; pp. 47–58. ISBN 978-1-118-83650-7.
133. Kato, H.; Araki, T.; Chen, T.; Itoyama, Y.; Kogure, K. Effect of Rolipram on Age-Related Changes in Cyclic AMP-Selective Phosphodiesterase in the Rat Brain: An Autoradiographic Study. *Methods Find Exp. Clin. Pharm.* **1998**, *20*, 403–408. [[CrossRef](#)] [[PubMed](#)]
134. Harada, N.; Nishiyama, S.; Ohba, H.; Sato, K.; Kakiuchi, T.; Tsukada, H. Age Differences in Phosphodiesterase Type-IV and Its Functional Response to Dopamine D1 Receptor Modulation in the Living Brain: A PET Study in Conscious Monkeys. *Synapse* **2002**, *44*, 139–145. [[CrossRef](#)] [[PubMed](#)]
135. Ramos, B.P.; Birnbaum, S.G.; Lindenmayer, I.; Newton, S.S.; Duman, R.S.; Arnsten, A.F.T. Dysregulation of Protein Kinase a Signaling in the Aged Prefrontal Cortex: New Strategy for Treating Age-Related Cognitive Decline. *Neuron* **2003**, *40*, 835–845. [[CrossRef](#)]
136. Paramanik, V.; Thakur, M.K. Role of CREB Signaling in Aging Brain. *Arch. Ital. Biol.* **2013**, *151*, 33–42. [[CrossRef](#)]
137. Wang, Z.; Zhang, L.; Liang, Y.; Zhang, C.; Xu, Z.; Zhang, L.; Fuji, R.; Mu, W.; Li, L.; Jiang, J.; et al. Cyclic AMP Mimics the Anti-Ageing Effects of Calorie Restriction by Up-Regulating Sirtuin. *Sci. Rep.* **2015**, *5*, 12012. [[CrossRef](#)]
138. Mathieu, L.; Lopes Costa, A.; Le Bachelier, C.; Slama, A.; Lebre, A.-S.; Taylor, R.W.; Bastin, J.; Djouadi, F. Resveratrol Attenuates Oxidative Stress in Mitochondrial Complex I Deficiency: Involvement of SIRT3. *Free Radic. Biol. Med.* **2016**, *96*, 190–198. [[CrossRef](#)]
139. Signorile, A.; Santeramo, A.; Tamma, G.; Pellegrino, T.; D'Oria, S.; Lattanzio, P.; De Rasmio, D. Mitochondrial CAMP Prevents Apoptosis Modulating Sirt3 Protein Level and OPA1 Processing in Cardiac Myoblast Cells. *Biochim. Biophys. Acta Mol. Cell Res.* **2017**, *1864*, 355–366. [[CrossRef](#)]
140. Valenti, D.; Manente, G.A.; Moro, L.; Marra, E.; Vacca, R.A. Deficit of Complex I Activity in Human Skin Fibroblasts with Chromosome 21 Trisomy and Overproduction of Reactive Oxygen Species by Mitochondria: Involvement of the CAMP/PKA Signalling Pathway. *Biochem. J.* **2011**, *435*, 679–688. [[CrossRef](#)]
141. Schapira, A.H.V.; Tolosa, E. Molecular and Clinical Prodrome of Parkinson Disease: Implications for Treatment. *Nat. Rev. Neurol.* **2010**, *6*, 309–317. [[CrossRef](#)]
142. Langston, J.W.; Ballard, P.; Tetrud, J.W.; Irwin, I. Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis. *Science* **1983**, *219*, 979–980. [[CrossRef](#)] [[PubMed](#)]
143. Choi, W.-S.; Kruse, S.E.; Palmiter, R.D.; Xia, Z. Mitochondrial Complex I Inhibition Is Not Required for Dopaminergic Neuron Death Induced by Rotenone, MPP+, or Paraquat. *Proc. Natl. Acad. Sci. USA* **2008**, *105*, 15136–15141. [[CrossRef](#)] [[PubMed](#)]
144. Choi, W.-S.; Palmiter, R.D.; Xia, Z. Loss of Mitochondrial Complex I Activity Potentiates Dopamine Neuron Death Induced by Microtubule Dysfunction in a Parkinson's Disease Model. *J. Cell Biol.* **2011**, *192*, 873–882. [[CrossRef](#)] [[PubMed](#)]
145. McWilliams, T.G.; Muqit, M.M. PINK1 and Parkin: Emerging Themes in Mitochondrial Homeostasis. *Curr. Opin. Cell Biol.* **2017**, *45*, 83–91. [[CrossRef](#)] [[PubMed](#)]
146. Pickrell, A.M.; Youle, R.J. The Roles of PINK1, Parkin, and Mitochondrial Fidelity in Parkinson's Disease. *Neuron* **2015**, *85*, 257–273. [[CrossRef](#)] [[PubMed](#)]
147. Zanellati, M.C.; Monti, V.; Barzaghi, C.; Reale, C.; Nardocci, N.; Albanese, A.; Valente, E.M.; Ghezzi, D.; Garavaglia, B. Mitochondrial Dysfunction in Parkinson Disease: Evidence in Mutant PARK2 Fibroblasts. *Front. Genet.* **2015**, *6*, 78. [[CrossRef](#)] [[PubMed](#)]
148. Pacelli, C.; De Rasmio, D.; Signorile, A.; Grattagliano, I.; di Tullio, G.; D'Orazio, A.; Nico, B.; Comi, G.P.; Ronchi, D.; Ferranini, E.; et al. Mitochondrial Defect and PGC-1 α Dysfunction in Parkin-Associated Familial Parkinson's Disease. *Biochim. Biophys. Acta* **2011**, *1812*, 1041–1053. [[CrossRef](#)]

149. Prasuhn, J.; Davis, R.L.; Kumar, K.R. Targeting Mitochondrial Impairment in Parkinson's Disease: Challenges and Opportunities. *Front. Cell Dev. Biol.* **2021**, *8*, 615461. [[CrossRef](#)]
150. Grünewald, A.; Kumar, K.R.; Sue, C.M. New Insights into the Complex Role of Mitochondria in Parkinson's Disease. *Prog. Neurobiol.* **2019**, *177*, 73–93. [[CrossRef](#)]
151. Sheng, B.; Wang, X.; Su, B.; Lee, H.-g.; Casadesus, G.; Perry, G.; Zhu, X. Impaired Mitochondrial Biogenesis Contributes to Mitochondrial Dysfunction in Alzheimer's Disease. *J. Neurochem.* **2012**, *120*, 419–429. [[CrossRef](#)] [[PubMed](#)]
152. Vrettou, S.; Wirth, B. S-Glutathionylation and S-Nitrosylation in Mitochondria: Focus on Homeostasis and Neurodegenerative Diseases. *Int. J. Mol. Sci.* **2022**, *23*, 15849. [[CrossRef](#)] [[PubMed](#)]
153. De Rasmio, D.; Ferretta, A.; Russo, S.; Ruggieri, M.; Lasorella, P.; Paolicelli, D.; Trojano, M.; Signorile, A. PBMC of Multiple Sclerosis Patients Show Deregulation of OPA1 Processing Associated with Increased ROS and PHB2 Protein Levels. *Biomedicines* **2020**, *8*, 85. [[CrossRef](#)]
154. Signorile, A.; Ferretta, A.; Ruggieri, M.; Paolicelli, D.; Lattanzio, P.; Trojano, M.; De Rasmio, D. Mitochondria, Oxidative Stress, CAMP Signalling and Apoptosis: A Crossroads in Lymphocytes of Multiple Sclerosis, a Possible Role of Nutraceuticals. *Antioxidants* **2020**, *10*, 21. [[CrossRef](#)] [[PubMed](#)]
155. Angelopoulou, E.; Pyrgelis, E.-S.; Piperi, C. Emerging Potential of the Phosphodiesterase (PDE) Inhibitor Ibudilast for Neurodegenerative Diseases: An Update on Preclinical and Clinical Evidence. *Molecules* **2022**, *27*, 8448. [[CrossRef](#)]
156. Ribaud, G.; Landucci, E.; Giannangeli, M.; Mazzantini, C.; Maccarinelli, G.; Mastinu, A.; Bonini, S.A.; Memo, M.; Pellegrini-Giampietro, D.E.; Gianoncelli, A. Virtual Screening and in Vitro Experiments Highlight Cannabidiol as a Drug-like Phosphodiesterase 9 Inhibitor. *Eur. J. Neurosci.* **2022**; *Online ahead of print*. [[CrossRef](#)]
157. Sheng, J.; Zhang, S.; Wu, L.; Kumar, G.; Liao, Y.; Gk, P.; Fan, H. Inhibition of Phosphodiesterase: A Novel Therapeutic Target for the Treatment of Mild Cognitive Impairment and Alzheimer's Disease. *Front. Aging Neurosci.* **2022**, *14*, 1019187. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.